Last reviewed · How we verify
Conventional orlistat 120 mg,
Inhibits pancreatic lipase to reduce fat absorption
Inhibits pancreatic lipase to reduce fat absorption Used for Obesity management.
At a glance
| Generic name | Conventional orlistat 120 mg, |
|---|---|
| Also known as | Xenical |
| Sponsor | Empros Pharma AB |
| Drug class | Lipase inhibitor |
| Target | Pancreatic lipase |
| Modality | Small molecule |
| Therapeutic area | Obesity |
| Phase | Phase 2 |
Mechanism of action
Orlistat works by inhibiting the enzyme pancreatic lipase, which breaks down fats in the intestine. This leads to a reduction in fat absorption and subsequent weight loss.
Approved indications
- Obesity management
Common side effects
- Oily spotting
- Fatty or oily stools
- Gas with oily spotting
- Fatty or oily diarrhea
- Abdominal pain
- Flatulence
- Diarrhea
- Increased bowel movements
- Nausea
- Vomiting
Key clinical trials
- A Trial With EMP16 in Preparation for Late Phase Studies (PHASE2)
- Study Exploring the Supportive Effect of Acarbose in Weight Management (PHASE2)
- A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers (PHASE1)
- Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional orlistat 120 mg, CI brief — competitive landscape report
- Conventional orlistat 120 mg, updates RSS · CI watch RSS
- Empros Pharma AB portfolio CI